Search clinical trials for: antibody drug conjugate (ADC)

Total 259653 results

ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
University of Texas Southwestern Medical Center
National Institute on Aging (NIA)

Completed

Aerobic Exercise Training in Mild Cognitive Impairment Study (AETMCI)

Mild Cognitive Impairment

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...

United States, Belgium, United Kingdom
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Peking University Cancer Hospital & Institute

Unknown

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
Fudan University

Active, not recruiting

The Rechallenge of ADCs in MBC Patients

Breast Cancer

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China
OBI Pharma, Inc

Terminated

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumor

United States
MacroGenics

Terminated

MGC018 With or Without MGA012 in Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Metastatic Castrate Resistant Prostate Cancer | Advanced Solid Tumor, Adult

Spain, United States, Australia, Poland
Open Innovation Partners, Inc.
Open Innovation Partners

Suspended

TR1801-ADC in Patients With Tumors That Express c-Met

Unspecified Adult Solid Tumor, Protocol Specific

United States
Pyramid Biosciences

Not yet recruiting

A Phase 1/2 Study of PBI-410 in Advanced Solid Tumors

Solid Tumor

United States
Progenics Pharmaceuticals, Inc.

Completed

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Completed

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Prostate Cancer

United States
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Centre Hospitalier Universitaire de Saint Etienne

Completed

Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares (ADC)

Low Back Pain

France
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
MedImmune LLC

Completed

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

Relapsed/Refractory Multiple Myeloma

United States, Australia, Spain, Greece
RemeGen Co., Ltd.

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Gastric Cancer

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Breast Cancer With Liver Metastases

China
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

Solid Tumor

China
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
Fudan University

Active, not recruiting

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Breast Cancer

China
TORL Biotherapeutics, LLC
Translational Research in Oncology

Recruiting

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

Hepatocellular Carcinoma | Advanced Solid Tumor

United States
Byondis B.V.

Recruiting

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Solid Tumor

Belgium, Italy, Netherlands, United Kingdom
Byondis B.V.

Completed

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

Solid Tumor

France, Belgium
Alligator Bioscience AB

Completed

ADC-1013 First-in-Human Study

Neoplasms | Solid Tumors

United Kingdom, Denmark, Sweden
Federal Research Institute of Pediatric Hematology...

Recruiting

DWI in the Diagnosis of Histological Types of Nephroblastoma in Children

Nephroblastoma (Wilms Tumour)

Russian Federation
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM501 in Patients With Solid Tumors

Advanced Solid Tumors

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
Jinling Hospital, China

Recruiting

A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma (1)

Carcinoma | Upper Tract Urothelial Carcinoma | UTUC

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Shanghai Miracogen Inc.

Completed

A Study of MRG003 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Ambrx, Inc.

Withdrawn

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

HER2 Mutation-Related Tumors | HER2 Amplified Solid Tumors

United States
Heinrich Elinzano, MD
University of Texas; Rhode Island Hospital; Progenics Pharmaceuticals, Inc.

Completed

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Gliosarcoma | GBM

United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | Burkitt's Lymphoma | Lymphoma, Marginal Zone

United Kingdom, United States, Italy
ADC Therapeutics S.A.

No longer available

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Metastatic Breast Cancer

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.

Refractory or Recurrent CD30+ Hematologic Malignancies

China
RemeGen Co., Ltd.

Completed

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors

China

Search clinical trials for: antibody drug conjugate (ADC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations